Atea Pharmaceuticals, Inc. (AVIR)
NASDAQ:AVIR
Want to see AVIR full AI Analyst Report?
Earnings Data
Report Date
Aug 06, 2026After Close (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
-0.56Last Year’s EPS
-0.44Same Quarter Last Year
Moderate Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call presents a largely positive outlook driven by strong operational progress: completed enrollment for the U.S. Phase 3 (C‑BEYOND), near‑complete enrollment ex‑U.S. (C‑FORWARD), a well‑powered trial design (90% power, 5% non‑inferiority), an advancing HEV program (CTA enabling studies done, FIH mid‑year), clear prescriber interest, manufacturing readiness, and $256M in cash with runway through 2027. Key risks include a limited cash runway beyond 2027, higher R&D spend, regulatory complexity (different primary analysis populations for FDA vs EMA), payer and market access uncertainties, and clinical/regulatory risk for the novel HEV program. On balance, operational milestones and program momentum outweigh the noted risks.Company Guidance
C-BEYOND Enrollment Completed and Imminent Top-Line Data
Completed patient enrollment for C-BEYOND in North America with >880 patients; top-line SVR24 (primary endpoint) results expected mid-2026; trial is randomized 1:1 vs the standard of care (Epclusa).
C-FORWARD Near-Complete Enrollment Supporting Broad Label
C-FORWARD (ex‑North America) has completed ~95% enrollment of cirrhotic and non-cirrhotic patients; enrollment remains open only to less prevalent genotypes (4, 5, 6) to support a broad label; top-line data expected around year-end 2026.
Robust Phase 3 Design and Statistical Power
Both Phase 3 trials are powered at 90% with a 5% non-inferiority margin and primary endpoint SVR24; expected SVR rates ~95% in the MITT population (consistent with Phase 2 results); company plans a combined analysis (shared with FDA) that could support a superiority claim.
Regimen Profile—Potential Best-in-Class Attributes
Bemnifosbuvir/ruzasvir (BEM‑RZR) demonstrates high efficacy and short treatment durations (8 weeks for cirrhotics vs 12 weeks for SOC in some groups), low drug‑drug interaction risk (no interaction observed with PPIs—used by ≈35% of HCV patients—and with statins), and no food effect; additional supportive data to be presented at EASL.
HEV Program Progress (AT‑587) with Clear Path to First‑in‑Human
CTA‑enabling GLP toxicology and safety pharmacology completed for AT‑587; first‑in‑human study anticipated mid‑year (single ascending and multiple ascending dose phases, MAD includes 7 days), proof‑of‑concept study planned around year‑end with a likely 12‑week treatment arm; preclinical data show strong potency against genotype 3, low DDI potential, predicted human exposure above in vitro EC50, and an estimated addressable market of $750M–$1B annually (≈3% of ~450k at‑risk patients in US/EU).
Commercial Positioning and Prescriber Interest
U.S. HCV market estimated at ~$1.3B (≈50% of a ~$2.6B global market); independent IQVIA research (153 high prescribers) indicated physicians would likely prescribe BEM‑RZR to ~50% of their patients; prescriber base is concentrated (~7.8k physicians write ~80% of DAA prescriptions), enabling a capital‑efficient commercial model with an estimated specialty sales force ~75.
Manufacturing and Supply Readiness
All components and processes for large-scale manufacturing are in place, commercial supply production is underway, expected low cost of goods relative to net pricing, and 4‑week blister card packaging planned to support adherence.
Solid Near-Term Financial Position
Cash and marketable securities of $256 million as of 03/31/2026; company projects this cash runway will extend through 2027 to fund Phase 3 completion, regulatory activities, and HEV program advancement.
AVIR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AVIR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 12, 2026 | $5.50 | $4.57 | -16.91% |
Mar 05, 2026 | $5.30 | $5.89 | +11.13% |
Nov 12, 2025 | $3.50 | $3.06 | -12.57% |
Aug 07, 2025 | $3.46 | $3.38 | -2.31% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Atea Pharmaceuticals, Inc. (AVIR) report earnings?
Atea Pharmaceuticals, Inc. (AVIR) is schdueled to report earning on Aug 06, 2026, After Close (Confirmed).
What is Atea Pharmaceuticals, Inc. (AVIR) earnings time?
Atea Pharmaceuticals, Inc. (AVIR) earnings time is at Aug 06, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AVIR EPS forecast?
AVIR EPS forecast for the fiscal quarter 2026 (Q2) is -0.56.